Opportunity Radar

← Back to search

Grant

Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)

View on Grants.gov ↗ Sign in to save

Type
Grant
Notice type
G
Agency
National Institutes of Health
Sub-agency
HHS-NIH11
Solicitation #
PAR-25-024
Posted
Oct 28, 2024
Response due
Jan 7, 2028
Archive date
Feb 12, 2028
CFDA / Assistance listing
93.853,93.866
Contact
grantsinfo@nih.gov
Source
Grants.gov

Description

The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this initiative is to deliver candidate biomarkers or biomarker signatures that are ready for definitive analytical and clinical validation studies.

Similar open opportunities